



3 May 2024

Successful completion of retail component of Entitlement Offer

SomnoMed Limited ACN 003 255 221 (**SomnoMed** or the **Company**) is today pleased to announce the successful completion of the retail component (**Retail Entitlement Offer**) of its 1 for 1.01 fully underwritten accelerated non-renounceable entitlement offer (**Entitlement Offer**).

The Retail Entitlement Offer closed on Wednesday, 1 May 2024 at 5:00pm (AEST).

Completion of the Retail Entitlement Offer represents completion of the second stage of the Company's capital raising announced on Tuesday, 9 April 2024 to raise approximately \$22.6 million. The first stage of the capital raising, being the approximately \$5.8 million institutional component of the Entitlement Offer (the **Institutional Entitlement Offer**), completed on Tuesday, 9 April 2024, as announced to the market by the Company on Wednesday, 10 April 2024.

The Retail Entitlement Offer provided eligible retail shareholders of the Company the opportunity to subscribe for 1 new fully paid ordinary share in the Company (**New Share**) for every 1.01 existing fully paid ordinary shares held in the Company as at 7:00pm (Sydney, Australia time) on Thursday, 11 April 2024 (**Entitlement**), at a price of \$0.21 per New Share. Eligible retail shareholders who took up their Entitlement in full under the Retail Entitlement Offer were invited to apply for additional New Shares (**Additional New Shares**), with any scale-back at the absolute discretion of the Company. The Company confirms that all shareholders who applied for Additional New Shares will have their applications allotted in full.

The Company received valid applications from eligible retail shareholders for approximately 56.0 million New Shares (including Additional New Shares) under the Retail Entitlement Offer, representing approximately 70% of the Retail Entitlement Offer size. Of the remaining approximately 24.0 million New Shares not taken up by eligible retail shareholders under the Retail Entitlement Offer, approximately 21.1 million New Shares have been allocated to sub-underwriters, with the balance of approximately 2.9 million New Shares allocated to TDM Growth Partners Pty Ltd (**TDM**). Including the New Shares allocated to sub-underwriters and TDM, the Retail Entitlement Offer raised a total of approximately \$16.8 million. The participation of TDM in the Entitlement Offer is expected to result in an increase to its shareholding to approximately 31.3%.

Settlement of the Retail Entitlement Offer is expected to occur on Tuesday, 7 May 2024, with the New Shares and Additional New Shares expected to commence trading on the ASX on Thursday, 9 May 2024.

Wilson's Corporate Finance Limited acted as sole lead manager, bookrunner and underwriter to the Entitlement Offer.

Terry Flitcroft
Company Secretary
SomnoMed Limited

For personal use only

Authorised for release to the ASX by Terry Flitcroft, Company Secretary

About SomnoMed

SomnoMed is a public company providing treatment solutions for sleep-related breathing disorders including obstructive sleep apnea, snoring and bruxism. SomnoMed was commercialised on the basis of extensive clinical research. Supporting independent clinical research, continuous innovation and instituting medical manufacturing standards has resulted in SomnoDent® becoming the state-of-the-art and clinically proven medical oral appliance therapy for more than 885,000 patients in 28 countries. For further information, visit SomnoMed at <http://www.somnomed.com.au>

NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES

This announcement has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the US Securities Act of 1933 (the **U.S. Securities Act**) and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration of the US Securities Act and applicable US state securities laws.

For personal use only